Abstract: A deodorant composition including a dialkyl amide in a dermatologically acceptable carrier, a method of preparing a cosmetic product intended for human topical application including the deodorant composition, a method for controlling malodor associated with human perspiration including the step of applying to the skin the deodorant composition, and a combination for use as a deodorant on human skin including the deodorant composition and a tube container, are disclosed herein.

Abstract: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: The invention provides combination therapies for treating papilloma virus.

Abstract: The present invention relates to insect repellant compositions containing, based upon the total weight of the composition, from about 6 to about 30 percent by weight of insect repellant active material having functionality selected from ester, amide, urethane or combinations thereof; from about 5 to about 30 percent by weight of alcohol, and from about 1 to about 10 percent by weight of nonionic surfactant. The compositions of the invention exhibit reduced rates of degradation of the active material in solution and are less drying and irritating to sensitive skin.

Abstract: A new composition for effecting serum cholesterol levels is claimed, said composition comprising a) at least a waxy acid with 23 to 50 carbon atoms or derivatives thereof and with serum cholesterol level reducing properties, and b) 0 to 99.99% by weight of at least a component with serum cholesterol level effecting properties, and c) 0 to 20% by weight of at least a pharmaceutically acceptable formulation aid. The efficacy of this composition can be enhanced by further incorporation of other cholesterol reducing agents, like lecithin, tocotrienol, saponins, fibers, long-chain waxy alcohols and niacin. The claimed composition combines the benefits of the single physiolocology active constituence together with the technology to increase the biovailability.

Abstract: The present invention relates to novel aromatic amines of general formula (I) and to the use of these amines for the treatment of obesity, anorexia, inflammation, mental disorders an other diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones.

Abstract: The present invention is directed to a method for treating bronchial constriction in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to produce bronchial dilation. The present invention is also directed to a method for treating airway disease in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in an amount from about 0.0001 millimoles to about 0.005 millimoles. The present invention is further directed to a method for treating airway disease in mammals. The method comprises contacting the mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to prevent bronchial spasm.

Abstract: This invention relates to compounds of the general formula 1

Abstract: The present disclosure describes methods for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The methods comprise administering a cardiac-sparing compound having a structure of formula (I) as described herein and a pharmaceutically-acceptable carrier.

Abstract: Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

Abstract: A bactericide and an anticeptic comprises at least an amide group-containing guanidine derivative represented by General Formula (I) or a salt thereof: 1

Abstract: The invention intends to provide a natural physiologically active material effective on fish diseases such as virus diseases, bacterial diseases and parasitic diseases when fed to fish by oral administration, and fish food containing the material.

Abstract: A non-toxic, environmentally safe and easily employable insecticide and insect repellent is achieved by providing an aqueous composition incorporating ethanolamine based compounds, either independently or in combination with the ethanolamine based compounds being selected from both simple compounds and conjugated compounds. In one preferred embodiment, a highly effective composition is attained for safe, effective, direct topical application to humans and animals by employing between about 10% and 70% by volume of the entire composition of the ethanolamine-based compound. In alternate preferred embodiments, the insecticide is formulated for application to plants, trees, crops, and other vegetation to provide a composition which effectively controls bothersome insects, while being completely safe and non-injurious to the plant, tree, or crop, as well as to the flowers or fruit thereof.

Abstract: A method is provided to parenterally administering an analgesic (i.e., fentanyl) to a patient in the presence of a cannabinoid receptor agonist. This has been found to unexpectedly result in an almost order of magnitude increase in the therapeutic index over that of administering fentanyl alone. The respective amounts of the cannabinoid receptor agonist and fentanyl are selected to achieve the therapeutic index of the analgesic is greater than about 1000. While the method of the present invention contemplates administering the drug by all the medication routes other than orally, the preferred route is via inhalation.

Abstract: The invention relates to a method for producing compounds of general formula (I), wherein R1 and R2, each time they occur and independently of each other, mean hydroxy, C1-6-alkyl, C1-6-alkoxy, halogen, phenyl or phenoxy; R3 means hydrogen or C1-6-alkyl; m is a whole number from 0 to 4; and n is a whole number from 0 to 5. According to said method, diketene is reacted with a N-phenyl-p-phenylenediamine of general formula (II), wherein R1, R2, R3, m and n have the meanings given above, in the presence of 3-40% acetic acid and at temperatures of 20 to 100° C., preferably 60 to 70° C. The invention also relates to the compounds (I) with R3=C1,6-alkyl and the enamines that can be obtained from these by reaction with ammonia, and their hydration products.

Abstract: The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform.

Abstract: Disclosed are multibinding compounds which are &bgr;2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma and bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Abstract: This invention relates to kavalactone-containing compositions, and more particularly to compositions having compounds derived from kavalactones and from capsaicinoids. The compositions are useful in modulating pain, and thus can be used to mediate, or eliminate, sensations of pain, thereby providing pain relief and reduction.

Abstract: The present invention provides methods and kits for treating back pain, especially chronic back pain. The methods comprise administering a vanilloid receptor agonist, preferably a capsaicin.

Abstract: A (2-substituted oxyphenyl)alkanamide derivative or a salt thereof expressed by the following Formula (I): wherein one of A and B is a hydrocarbon group of C3-30 expressed by R1 and the other is —(CH2)n-NR2R3; Z is —CO— or —CONR6—; R2 and R3 individually represent H, lower alkyl or benzyl, or —NR2R3 may be a heterocycle having 3-7 members; wherein —CONR5—(CH2)n-NR2R3 or —CONR6—(CH2)n-NR2R3 may be the following Group (II): wherein ring Y is a heterocycle of 6 or 7 members; R4 is selected from the group consisting of H, halogen, lower alkyl, lower acyl and etc; R5 and R6 are individually H, lower alkyl, lower acyl or lower alkylcarbamoyl, or may form a part of said Group(II); 1 is 0 or 1; m is 1 or 2; and n is an integer of 0-5.

Abstract: The invention relates to the modulation of gene expression. In particular, the invention relates to compositions comprising antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of a product of that gene, and methods of using the same.

Abstract: The compound of the formula (I) 1

Abstract: The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): 1

Abstract: A composition for use in treating or preventing mucositis, and/or xerostomia, including capsaicin or capsaicin derivative, and one or more additional compounds useful in treating mucositis and/or xerostomia, wherein the composition is provided in an oral delivery vehicle. The invention also relates to a method of treating or preventing mucositis and/or xerostomia, and a method for preparing such a composition.

Abstract: The invention described herein encompasses methods and compositions of preventing or treating cancer comprising the administration of a combination of catechins and vanilloids. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). In a preferred embodiment the catechins have been treated with tannase. Compositions of vanilloids include, but are not limited to vanillylamine, the head group of capsaicin. The unique compositions of the invention contain various combinations of the catechins and vanilloids, in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses various modes of administration of the therapeutic compounds, including formulations which may be used as a dietary or nutritional supplement or as a therapeutic compound.

Abstract: The present invention relates to a method for treating eosinophilic granuloma in a Feline comprising administering a pharmaceutical composition, the composition comprising N-palmitoylethanolamide. The present invention also relates to said pharmaceutical composition and the process for the preparation thereof.

Abstract: This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar1, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.

Abstract: A pharmaceutical composition intended for oral use contains the effective ingredient(s), capsaicin, and other typical fillers and excipients. The composition is preferably in the form of a solid oral dosage form. Transdermally administered compositions are also within the purview of the invention. Aside from the effective pharmaceutical ingredient(s) the composition includes an amount of capsaicin which serves as a deterrent to the intranasal, intravenous, or oral abuse of the composition. Such a composition deters abusers from crushing prescription pharmaceutical tablets for abusive snorting, injection, or ingestion.

Abstract: A Type IV crystal of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide hydrochloride, which can be produced by crystallization using a solvent containing water at 2% by weight at the maximum and which has a X ray powder diffraction pattern containing peaks at least at 13.4°, 18.7°, 19.4°, and 22.5° (2&thgr;), is provided. This compound is useful as an effective ingredient for a carcinostatic agent. The crystal of the present invention has excellent properties desirable from the standpoint of the production of medicinal products, i.e., reduced water adsorption and extremely high stability to water. Also provided are a method for producing the Type IV crystal thereof and a method for use of the crystal.

Abstract: The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula I wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

Abstract: The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and/or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio/chemo protectants. The invention is also directed to treatment and prevention of infections associated with mucositis by topical application of amifostine and related compounds.

Abstract: Cosmetic, dermatological and pharmaceutical compositions containing quaternary ammonium compounds, particularly for hair-treatment, require low setting points, good solubility and dispersibility in aqueous media and a low flash point. It has now been found that such compositions can be formulated with quaternary ammonium compounds essentially free of short-chain alcohols, such as isopropanol.

Abstract: Methods, pharmaceutical compositions, and compounds for reducing body weight, modulating body lipid metabolism, and reducing food intake in mammals are provided. The compounds of the invention include fatty acid ethanolamide compounds, homologues and analogs of which the prototype is the endogenous fatty acid ethanolamide, oleoylethanolamide.

Abstract: Compounds of the formula: are provided, and are useful as cysteine protease inhibitors, particularly in the treatment of diseases such as osteoporosis or autoimmune disorders in which cathepsins K or S contribute to the pathology or symptomatolgy of the disease.

Abstract: The present invention relates to compounds according to the general formula (I), 1

Abstract: Described are cyclohexylamine derivatives of Formula I 1

Abstract: Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

Abstract: The subject invention provides a method of treating mania in bipolar disorder in a subject comprising administering to the subject a therapeutically effective amount of derivatives of 1-aminoindan or their racemic mixtures, enantiomers, or salts, of the general formula: wherein n is 0 or 1; each of R1 and R2 are hydrogen, C1-C4 alkyl, halogen; R3 is hydrogen, C1-C4 alkyl, hydroxy, C1-C4 alkoxy; R4 is hydrogen, C1-C4 alkyl; R6 is hydrogen, substituted or unsubstituted C1-C12 alkyl, C6-C12 aryl, C7-C12 aralkyl or A—N—R9R10, provided that R6 is not methyl when R1, R2, R3 and R4 are hydrogen atoms, wherein A is substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C7-C12 aralkyl, and each of R9 and R10 are independently hydrogen, C1-C12 alkyl, C6-C12 aryl, C7-C12 aralkyl, COOtBu, or indanyl; and racemic mixtures, enantiomers, and salts thereof.

Abstract: A method of treating Mild Cognitive Impairment (MCI) has been discovered. The treatment includes administering an effective amount of a natural product that increases soluble amyloid precursor protein (APPs) expression. Examples of a natural product suitable for the method include, but are not limited to, resveratrol, capsaisin, olvanil, resiniferatoxin, arvanil, linvanil, capsazepine, or combinations of these naturally occurring substances. The treatment can also be used to prevent or alleviate the dementia, or to delay its onset. Moreover, a foodstuff is disclosed that incorporates a natural product useful in treating MCI.

Abstract: Compounds of formula (I) 1

Abstract: 3,4,5-trisubstituted aryl nitrone compounds having the formula: 1

Abstract: Gamma-hydroxybutryic acid amides are used in the treatment of drug addiction and especially in the treatment of alcoholism.

Abstract: The present invention thus provides compounds of Formula I: 1

Abstract: The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

Abstract: Pharmaceutically-active materials comprising specific antidepressant compounds, such as sertraline, contained in microparticles formulated so as to release the antidepressant compounds over an extended period of time are disclosed. The materials, when administered, particularly by injection, release the active agent over time allowing the patient to be effectively treated without requiring multiple dosing of the pharmaceutical material. Pharmaceutical compositions containing the microparticles and methods of treating depression-related conditions utilizing the microparticles are also disclosed.

Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.

Abstract: Compounds of formula I in which R1 denotes hydrogen or methyl R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms R3 denotes hydrogen or lower alkyl n denotes 0-12 R4 denotes alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of osteoporosis.

Abstract: The present invention provides methods for extending the life span of a subject and methods for inducing molecular changes within a whole organism that are responsible for the extended life span of the organism; therefore, providing a whole organism system to identify molecules involved in the ageing process.

Abstract: A method of treating cells that carry at least one APOE4 allele comprises increasing nitric oxide levels in the cells (e.g., by administering an exogenous source of nitric oxide to the cells) by an amount sufficient to combat the decrease of nitric oxide level associated with the presence of the APOE4 allele. Also disclosed is a method of increasing nitric oxide levels in cells in need thereof which comprises administering APOE to the cells in an amount sufficient to increase nitric oxide levels in the cells.

Abstract: Substituted trifluoromethyl ketones, ketooxazoles, ketoamides, ketoesters, and diketones having the formula 1